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ABSTRACT 
    Telomerase is a ribonucleoprotein with its catalytic subunit telomerase reverse 
transcriptase (TERT) as a key component, lengthening telomeres. In differentiated 
human cells, telomerase is silent due to the transcriptional repression of the TERT 
gene, but activated in oncogenesis. Telomerase activation/TERT induction is essential 
to unlimited proliferation of cancer cells via telomere lengthening, whereas recent 
evidence also suggests that TERT may be a master contributor of cancer hallmarks. It 
is thus important to define regulatory mechanisms underlying cancer-specific TERT 
expression, and to delineate oncogenic effects of TERT. This thesis is designed to 
address these issues with the following specific aims: (1) The association between 
single-nucleotide polymorphisms (SNPs) of the TERT gene and cancer susceptibility 
and (2) Biological/translational implications of cancer-specific TERT promoter 
mutations.  
    The TERT SNP association with cancer risk has been extensively investigated, 
most studies being focused on rs2736100 and rs2736098. The rs2736100_CC 
genotype has been shown to be associated with higher risk for a number of cancer 
types. Consistently, we observed that male individuals carrying the rs2736100_CC 
exhibited greater susceptibility to myeloproliferative neoplasms (MPNs), clonal 
diseases with myeloid cell origin (PAPER I). Furthermore, a comparison between 
Swedish and Chinese populations revealed a significantly higher fraction of 
rs2736100_CC in Swedes, coupled with a higher MPN incidence (compared to that in 
China). In addition, we made the same genotyping in upper tract urothelial carcinoma 
(UTUC) and hepatocellular carcinoma (HCC). The rs2736100_AC genotype was 
associated with reduced UTUC risk compared to the rs2736100_AA and CC carriers 
(PAPER II), while there were no significant differences in the rs2736100 or rs2736098 
genotype distribution between HCC patients and healthy individuals (PAPER III). 
Collectively, male/female and ethnical groups may harbor different germline TERT 
variants, thereby contributing to different incidences and susceptibility dependent on 
origins of malignancies. 
    The recurrent TERT promoter mutations, recently identified in different human 
malignancies, stimulate TERT transcription and activate telomerase. To explore the 
biological and clinical implication of TERT promoter mutations, we sequenced the 
TERT promoter region in tumor specimens derived from patients with UTUC, bladder 
cancer (BC) and HCC (PAPERS III and IV), and mutations were observed in 65/220 
(30%) UTUC, 41/70 (59%) BC and 57/190 (30%) of HCC patients, respectively. In 
UTUC, the presence of TERT promoter mutations was significantly correlated with 
metastases, whereas for HCC, there was a significant difference in rs2736098 and 
rs2736100 genotypes between wt and mutant TERT promoter-bearing tumors. The 
cancer risk genotype rs2736100_CC was significantly associated with a reduced 
incidence of TERT promoter mutations, while the rs2736098_CT genotype was 
significantly higher in HCCs with TERT promoter mutations. Thus, the germline 
TERT genetic background may substantially affect the incidence of TERT promoter 
mutations in HCCs. 
    As TERT promoter mutations are absent in normal cells, we evaluated the mutant 
TERT promoter as a urinary biomarker for non-invasive detection of UTUC and BC. 
The mutant TERT promoter was indeed detectable in urine from the mutation-positive 
UTUC and BC patients using Sanger sequencing, but the sensitivity was only 60%. To 
improve it, we developed a Competitive Allele-Specific TaqMan PCR (castPCR), and 
achieved an overall sensitivity of 89% and specificity of 96%. Thus, castPCR assays of 
TERT promoter mutations may be useful tools for non-invasive, urine-based 
diagnostics of UTUC and BC. 
    In summary, our findings gain new insights into the association of TERT SNPs 
with cancer risk and TERT promoter mutations. These results will hopefully contribute 
to the rational development of a TERT-based strategy for precision oncology. 
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1 INTRODUCTION 
1.1 Telomere 
1.1.1 Telomere structure and shelterin proteins 
Telomere is the special structure at the ends of chromosomes. The story dates back to the 
last century. In 1930s and 1940s, both Hermann J Muller and Barbara McClintock found 
that broken chromosomes were unstable and prone to rearrangements and fusion, which 
earned them the Nobel Prize in 1946 and 1983, respectively [1-3].  
In human, telomere is TTAGGG repeats up to 20 kb long. Telomere structure consists of 
double stranded DNA sequences with 3’ G rich tails and protein complexes [4-6]. The 
3’overhangs usually invade and insert into the double stranded telomere repeats to form 
a T-loop, which makes the chromosome stable. The protein complexes include those 
directly binding to telomeric DNA and their interacting factors. The most important 
members of binding proteins are collectively named shelterins, consisting of TTAGGG 
repeat binding protein factor 1 (TRF1), TRF2, POT1, TIN2, TPP1 and RAP1. TRF1 and 
TRF2 bind to the double stranded telomeric DNA, while POT1 binds the single strand 
overhang [7]. They interact with RAP1, TIN2 and TPP1 to regulate T-loop formation 
and maintain chromosome structure stability [8]. 
1.1.2 Telomere function 
Telomere and its binding proteins form a complex structure at the end of the 
chromosome, protecting chromosomes from end-to-end fusions, double-strand breaks 
and degradation [9]. Importantly, most normal human cells exhibit progressive telomere 
shortening with cellular division due to “the end replication problem”, and when 
telomere length becomes too short to maintain its function and structure, cells stop 
dividing and enter into a permanent growth arrest or senescent stage [10]. Therefore, 
telomere shortening serves as a mitotic clock, counting/controlling the number of cell 
population doublings. By doing so, telomere shortening prevents unlimited cell 
proliferation and thus form a strong barrier to immortalization and malignant 
transformation [11].  
1.2 Telomerase 
1.2.1 Discovery of telomerase and its structure/function 
Telomerase is a RNA-dependent DNA polymerase that extends TTAGGG repeats at the 
end of chromosomes. In 1987, Carol Greider and Elizabeth Blackburn discovered the 
enzyme to be a ribonucleoprotein complex critically dependent on both the protein and 
RNA component and named it as telomerase. They received the Nobel Prize in 2009 
[12]. 
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Telomerase consists of an RNA template (TERC), telomerase reverse transcriptase 
(TERT) and other components [13]. TERT is the catalytic, rate-limiting subunit of the 
enzyme. TERC is constitutively expressed in normal human cells, while TERT is absent 
in most differentiated human cells. In general, TERT expression is highly correlated 
with telomerase activity and lack of TERT expression leads to telomerase silence in 
normal human cells where progressive telomere erosion occurs, as described above. On 
the other hand, different levels of TERT/telomerase expression are detectable in 
stem/progenitor cells, activated lymphocytes and other cells with high proliferative 
potentials and required for their sustained proliferation by compensating for telomere 
loss [14].  
1.2.2 Biological role of telomerase in oncogenesis 
In most human somatic cells, telomerase is silent and TERT expression is repressed, and 
these cells have finite lifespan and telomeres shorten with cell division [15-17]. 
However, telomerase activation occurs widely in tumor cells to maintain telomere 
length, thereby overcoming proliferation limitation and senescence. Experimentally, 
ectopic TERT expression and telomerase activation is absolutely required for 
oncogene-mediated transformation of normal fibroblasts [18]. Furthermore, telomerase 
or TERT inhibition leads to the loss of tumorigenic potential of cancer cells. Consistent 
with these data, numerous clinical studies showed TERT/telomerase activity to be 
detectable in up to 90% of malignancies [19-20]. Therefore, telomerase activation is an 
essential step in malignant transformation. TERT, as a rate-limiting unit for telomerase 
activity, is equally critical to cancer development. 
Telomere elongation is an established function of telomerase or TERT, however, 
accumulated evidence suggests novel properties of TERT without involvement of 
telomere maintenance [21]. Ectopic expression of TERT promotes carcinogenesis 
independently of telomere lengthening, or stimulates cell proliferation by up-regulating 
growth factor expression [22]. TERT was recently shown to interact with NF-κb p65, 
activating NF-κb target genes [23]. TERT was associated with β-catenin, and synergized 
with β-catenin to induce epithelial-mesenchymal transition, thereby facilitating cancer 
metastasis [24]. Importantly, our recent findings further revealed a key role of TERT in 
self-renewal and expansion of prostate CSCs [25]. In addition, TERT enhances the 
chromatin-remodeling factor Brg1 recruited to β-catenin targets, promoting normal stem 
cell proliferation [26]. Thus, TERT plays parts far beyond its telomere-lengthening 
activity in cancer biology, significantly contributing to multiple cancer hallmarks. 
1.3 Regulation of TERT expression 
Given an important role of TERT/telomerase in oncogenesis, its regulatory mechanism 
has long been a central issue addressed in cancer research. TERT expression is 
controlled at multiple levels by many factors [27-30], however, it is predominantly 
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regulated at the transcriptional level. The TERT promoter is a region with GC-rich 
content rather than with a TATA box, which contains at least five upstream Sp1 binding 
motifs, two E-boxes and a single transcription start site that binds multi-functional 
transcription factor TFII-I [31-32].  
1.3.1 Positive regulators of TERT transcription 
The c-Myc oncogene, promoting cell growth and proliferation in a variety of human 
cancer, is a key trans-activator for the TERT gene. The TERT proximal promoter harbors 
two E-boxes with the sequence of 5’-CACGTG-3’, which are bound by c-Myc [33-35]. 
The c-Myc-induced TERT over-expression is one of the important mechanisms 
underlying its oncogenic potential [34]. 
Another key molecule in TERT regulation is Sp1 family transcription factors. Sp1 is a 
Zinc-finger transcriptional factor binding to GC boxes in promoters [31]. It directly 
stimulates or co-operates with c-Myc to activate TERT transcription [36].  
Besides c-Myc and Sp1, many other positive transcriptional factors regulate TERT 
transcription directly or indirectly. For example, the E26 transformation-specific (ETS) 
family proteins regulate TERT transcription by interacting with their binding motifs in 
the proximal promoter region [37-38]. Survivin could enhance TERT transcription by 
increase DNA binding ability [39]. Hypoxia-inducible factor-1α (HIF-1α) was observed 
to stimulate TERT transcription by binding to the TERT promoter in cancer cells [40]. 
Activating enhancer-binding protein-2 (AP-2) is capable of facilitating TERT 
transcription in lung cancer cells [41]. 
1.3.2 Negative regulators of TERT transcription 
The TERT gene is stringently repressed at the transcriptional level in normal 
differentiated human cells, however, the underlying mechanism remains incompletely 
understood. The tumor suppressors Mad1, TGF-β and Menin were identified as key 
negative factors repressing TERT transcription in normal fibroblasts [42]. Consistently, 
Mad/Max/c-Myc network proteins were also shown to be the master regulator of the 
TERT transcription in human cancer cells [34]. Mad is expressed in non-proliferating 
cells, and has the role to promote cell differentiation and prevent malignant 
transformation. Mad/Max heterodimers competitively binds to E-boxes on the TERT 
promoter to repress TERT transcription [43]. In HL60 leukemic cells, TERT mRNA is 
highly expressed because c-Myc binds to the E-boxes on the TERT promoter. Once cells 
are induced to undergo terminal differentiation, c-Myc expression is diminished whereas 
Mad1 levels increase and subsequently replace c-MYC on the TERT promoter, thereby 
silencing TERT transcription [34, 44]. Tollefsbol’s group determined the TERT gene 
trans-activation by endogenous c-Myc during the conversion from normal to 
transformed human fibroblasts, and they found that the induction of c-Myc expression 
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led to a switch from Mad1/Max to c-Myc/Max binding to sequences containing the 
TERT promoter distal and proximal E-boxes, coupled with telomerase activation [45]. 
P53, as a tumor suppressor, regulates cell proliferation, differentiation, apoptosis and 
senescence. It interacts with Sp1, a TERT activator binding to the TERT promoter, 
thereby attenuating the role of Sp1 in TERT transcription [46-47]. Thus, wild-type P53 
leads to decreased TERT expression and telomerase activity in cancer cells. 
In addition, many other transcriptional factors also negatively regulate TERT 
transcription. For instance, Wilms’ tumor 1 (WT1) [48-49], Rb, Ap1 and TGF-β/SMAD 
all down-regulate TERT transcription [50-52]. 
1.4 TERT gene polymorphisms and its promoter mutations 
According to recent genome-wide association studies (GWAS), single nucleotide 
polymorphisms (SNPs) are associated with susceptibility of human malignancies 
[53-56].  
The genetic variation in the TERT gene and cancer-specific expression of TERT or 
telomerase activity play an important role in malignant transformation and cancer 
progression. More recently, TERT promoter mutations have been identified as important 
genetic events that trigger telomerase activation in different types of cancer [57-65]. 
1.4.1 Single nucleotide polymorphisms (SNPs) of the TERT gene and 
cancer susceptibility 
The association between TERT rs2736100 and rs2736098 variants and cancer  
The presence of multiple SNPs in the TERT gene has been documented, among which 
rs2736100 (located at intron 2) and rs2736098 (at exon 2) are most studied. We and 
others previously analyzed the rs2736100 association with lung cancer risk, and 
observed a significantly elevated risk in C variant-carriers [66]. Recently, the 
rs2736100_C allele was further identified to be more intimately associated with female, 
non-smoking, EGFR-mutation-positive lung adenocarcinoma [67]. In addition, the 
rs2736100_C has also been shown to be a risk allele for malignant glioma, colorectal 
carcinoma, cervical, pancreatic, bladder, and ovarian cancer, acute myeloid and 
lymphoblastic leukemia, and other malignancies [68]. rs2736098 variants and 
association with cancer risk have also been demonstrated in multiple types of cancer 
including hepatocellular carcinoma (HCC), lung cancer, breast cancer, and more others 
[69-72]. However, it is unclear whether the TERT variants are associated with upper 
tract urothelial carcinoma (UTUC) risk or disease progression.  
The mechanism underlying the association between TERT variants and cancer 
susceptibility remains poorly defined. The rs2736100_CC genotype was shown to 
promote TERT transcription and to maintain telomere length much more strongly than 
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its AA and AC variants [67], which provides a potential explanation for linking 
rs2736100_CC genotype with cancer risk. It is not established whether there exist other 
mechanisms, and further investigations are required to elucidate this issue. 
1.4.2 TERT promoter mutations in human cancer 
In 2013, the hotspot TERT promoter mutation was first reported in human melanoma. 
Huang et al and Horn et al identified somatic mutations in the TERT promoter region in 
malignant melanoma [56, 73]. Two major point mutations are named C228T and C250T, 
which are cytidine-to- thymidine change occurring at -124 and -146 from the translation 
start site, respectively. These mutations create a new ETS binding motif, and thereby 
activate TERT transcription [58, 74] (Figure 1). Since then, TERT promoter mutations 
have been identified in many types of cancer. TERT promoter mutations occur most 
frequently in bladder, renal pelvic, thyroid cancer, HCC, malignant glioblastoma and 
melanoma [75], while they are rarely present in hematological malignancies, prostate, 
gastrointestinal, breast and lung cancer [57, 76]. Many studies demonstrate that tumors 
bearing the mutant TERT promoter in general express higher levels of TERT mRNA 
than those with a wild type promoter [77-78]. 
 
 
 
In addition to C228T and C250T mutations, other mutations with a low frequency are 
also identified in the TERT promoter region. For example, CC-to-TT tandem mutations 
occur at -124/-125 and -138/-139, and the C-to-T mutation at -57, are found in a small 
proportion of cancer [56]. All these mutations contribute to enhanced TERT 
transcription by creating new transcriptional factor binding sites. 
1.4.3 Overview of myeloproliferative neoplasms (MPNs) 
MPNs are a group of clonal disorders within the myeloid lineages in the bone marrow 
[79]. MPNs have the character of hyperproliferation, resulting in excessive number of 
terminally differentiated cells from one or more of myeloid lineages. MPNs are 
sub-grouped into polycythemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF) [80].  
Figure 1. The structure of TERT promoter and positions of C228T and C250T. 
C>T mutations lead to new ETS1 binding sites, therefore promoting TERT 
transcription. 
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A number of important genetic alterations have been identified in MPNs and the most 
common one is the JAK2
V617F
 mutation, which is observed in 95% of PV, 50% of ET 
and PMF [81-82]. Other genetic aberrations include calreticulin (CALR), MPL 
mutations, etc. [83]. All these mutations are believed to act as drivers for MPN 
development. 
1.4.4 Telomere biology in MPNs and efficacy of telomerase inhibition 
A number of studies have reported that telomere length in MPN patients is shorter than 
that in the healthy population, and shorter telomere length in bone marrow cells 
indicated MPN progression [84-86]. Moreover, we observed a widespread dysregulation 
of shelterin factor expression [87-88], and this together with shortened telomere length 
significantly contributed to telomere dysfunction and genomic instability occurring in 
MPNs. Thus, aberrant telomere length and shelterin protein expression play an important 
part in the pathogenesis of MPNs. In addition, the variant at SNP rs2736100 has recently 
been reported to be associated with MPN susceptibility [89-90]. 
The above findings promoted testing of the telomerase inhibitor GRN163L (Imetelstat®) 
in MPN treatment. GRN163L inhibits telomerase activity by interfering with TERC 
function. In PMF, approximately one-fifth of patients (7/33) treated with Imetelstat® 
either had a complete remission (CR) (defined as normalization of hepatosplenomegaly, 
blood counts including white blood cell differential together with reversal of bone 
marrow fibrosis) or a partial remission (defined with the same criteria as for complete 
remission apart from reversal of the bone marrow fibrosis) [91]. In addition, GRN163L 
could significantly inhibit megakaryocyte maturation in MPNs, thereby achieving its 
efficacy in ETs [92].  
1.5 Upper tract urothelial carcinomas (UTUCs) 
1.5.1 Overview 
Urothelial carcinomas are malignant tumors that arise from the urothelial epithelium and 
may involve the lower urinary tract (bladder and urethra) [93] or the upper urinary tract 
(renal pelvis and ureter) (Figure 2). 
UTUCs, like bladder cancer (BC), belong to transitional cell carcinomas and consist 
predominantly of renal pelvic carcinomas (RPCs) and ureter carcinomas (UCs). UTUCs 
account for 5% to 10% of all primary urothelial cancers [94], and their recurrence and 
progression rates are high due to difficulties in early diagnosis [95]. Therefore a better 
understanding of UTUC pathogenesis might lead to early identification, and hence 
improved therapeutic possibilities. 
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1.5.2 Treatment 
Urothelial carcinoma is the ninth most common cancer globally and the eighth most 
lethal neoplasm in men in the United States [96-97]. It is the most costly cancer in the 
US health care system on a per-patient basis, because these patients are prone to frequent 
relapses and need life-long surveillance.  
Surgery is the mainstay of UTUC therapy, but the prognosis remains poor. Recently, 
there is increasing enthusiasm for combined-modality approaches in both the adjuvant 
and neoadjuvant settings. Nephron-sparing surgical strategies, including partial 
ureterectomy and purely endoscopic tumor resection, are also increasingly used [98]. 
1.6 Hepatocellular carcinoma (HCC) 
1.6.1 Overview 
HCC is derived from primary liver cells and represents 70-85% of primary liver cancer 
[99]. It is the fifth most common cancer in men and the seventh in women, being 
diagnosed in more than half a million individuals worldwide every year [100]. The main 
risk factor for HCC include hepatitis B (HBV) and hepatitis C (HCV) infection 
[101-104], and liver diseases caused by excessive alcohol consumption, aflatoxin 
exposure, and non-alcoholic fatty liver disease [100, 105-107].  
1.6.2 The role of TERT in HCC 
Several studies have reported the correlation between TERT and HCC [108-111]. A 
recent study showed that TERT promoter mutations were identified as the most frequent 
genetic alterations in HCC with an overall frequency around 60% [112]. Moreover, 
Figure 2.The diagram shows the location 
of UTUCs and BCs. 
RPC, Renal pelvic carcinoma; UC, Ureter 
carcinoma; BC, Bladder cancer.  
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SNPs rs2736098 on the TERT gene and rs2853669 on TERT promoter region were 
found to be associated with increased risk and poor prognoses of HCC [113-115]. 
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2 AIMS OF THE STUDY 
The overall aim of this PhD project is to define the association between the TERT SNPs 
and cancer susceptibility, relation to TERT promoter mutations, new roles of TERT and 
telomerase in cancer development/progression, and their clinical relevance. Specifically, 
the study is aimed at: 
1) Determining whether there exist disparities in the rs2736100 distribution 
between Chinese and European populations and its relation to MPN 
susceptibility. 
 
2) Determining whether the rs2736100/rs2736098 variants in the TERT gene are 
associated with UTUC and HCC susceptibility. 
 
3) Defining whether the germline variants in the TERT gene affect the incidence of 
TERT promoter mutations in UTUC and HCC.  
 
4) Evaluating the detection of mutant TERT promoter sequences as urinary 
biomarkers for non-invasive UTUC diagnosis and disease surveillance. 
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3 METHODS 
3.1 Patients and healthy controls (PAPERS I-IV) 
3.1.1 MPN patients and healthy controls (PAPER I) 
One hundred and one Chinese MPN patients and 101 age- and gender- matched healthy 
adults were recruited from Shandong University Hospitals, China. One hundred and 
twenty-six patients, diagnosed with MPN at Karolinska University Hospital were 
included in the study. Age-and-gender matched Swedish healthy adults (N=756) were 
used as controls for the Swedish MPN patients. Peripheral blood was collected from 
both MPN patients and controls and myeloid cells then isolated. 
3.1.2 UTUC patients and healthy controls (PAPERS II & IV) 
In PAPER II, 212 recently diagnosed UTUC patients were recruited from the Shandong 
University Qilu Hospital and the Second Hospital, and 289 age- and gender- matched 
healthy adults were used as control populations. Both patients and controls have Han 
Chinese ethnic background. Tumors and their adjacent normal tissues were collected 
from patients. Peripheral blood was collected from healthy controls and mononuclear 
cells then isolated. 
In PAPER IV, 98 patients with RPC, 122 with UC and 70 with BC were recruited from 
Shandong University Qilu Hospital and the Second Hospital, China. Spontaneously 
voided urine was collected from 16 RPC, 20 UC and 70 BC patients prior to surgical 
treatment. In 13 of 36 RPC and UC patients, urine was also obtained one week after 
surgery.  
3.1.3 HCC patients and healthy controls (PAPER III) 
Two hundred and forty-five newly diagnosed HCC patients were recruited from 
Shandong University Second Hospital and Shandong Provincial Hospital. Sex-matched 
healthy adults served as controls. Age (mean±SD) for patients and controls was 45±16 
years and 54±10 years, respectively. Both patients and controls have Han Chinese 
ethnic background. Tumors and their adjacent normal tissues and blood were collected 
from HCC patients. Peripheral blood was collected from healthy controls and 
mononuclear cells then isolated. 
3.2 Telomere length analysis using flow-FISH (PAPER I) 
The average telomere length was measured with flow-FISH following the protocol by 
Baerlocher et al. [116], with minor modifications. Calf thymocytes were kindly donated 
from Ö-slakt AB (Värmdö, Stockholm). Stained cells were captured with Gallios flow 
cytometer (Beckman Coulter, Brea, CA, USA) and the analysis was done using the 
Kaluza software (Beckman Counter, Brea, CA, USA). Fluorescent MESF-FITC beads 
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(Bangs Laboratories, Fisher, IN, USA) were used and the fluorescent signal was 
quantified using the QuickCal v.2.3 data analysis program (Bangs Laboratories, Fishers, 
IN, USA). 
3.3 RNA extraction and quantitative real-time PCR (PAPER I) 
Total RNA from MPN patients was isolated using TRIzol reagent (Life technologies, 
Carlsbad, CA, USA). Two g of RNA was used for reverse transcription using M-MLV 
(Life technologies, Carlsbad, CA, USA) according to the recommended protocol. 
Real-time amplification was performed in triplicate using SYBR Green PCR Master Mix 
(Life technologies, Carlsbad, CA, USA) with QuanStudio 7 Flex Real-Time PCR 
System (Applied Biosystems, Waltham, MA, USA). The primers used in this study are 
listed in Table 1. 2 microglobulin (2-M) was used as the internal control and 2-Ct 
method was used to calculate relative mRNA expression [117]. 
Table 1. Primers used for quantitative real-time PCRamplification of gene expression 
TERT 
Forward 5’-CGGAAGAGTGTCTGGAGCAA-3’ 
Reverse 5’-GGATGAAGCGGAGTCTGGA-3’ 
2-M 
Forward 5’-GAATTGCTATGTGTCTGGGT-3’ 
Reverse 5’-CATCTTCAAACCTCCATGATG-3’ 
3.4 DNA extraction (PAPERS I-IV) 
In PAPER I, DNA was isolated using QIAmp DNA blood kit (QIAGEN, Hilden, 
Germany) from both Swedish and Chinese MPN patients and Chinese healthy controls. 
For Swedish healthy controls, DNA was extracted from saliva using Oragene saliva 
collection kit (DNA Genotek Inc., Ottava, Canada) [118]. 
In other PAPERS, DNA was extracted using QIAGEN DNA extraction kits (QIAGEN) 
and the concentration was measured by NanoDrop™ 2000 Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA, USA). 
3.5 Genotyping of TERT rs2736098 and rs2736100 (PAPERS I-III) 
The TERT rs2736098 (T/C) and rs2736100 (A/C) genotyping was performed using 
pre-designed TaqMan SNP genotyping assay kits on a QuanStudio 7 Flex Real-Time 
PCR System (Applied Biosystems, Waltham, MA, USA) [119]. Both positive and 
negative controls were included in all assays and the running condition was as followed: 
95℃ for 10 min followed by 40 cycles of 92℃ for 15s and 60℃ for 1 min. 
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3.6 Sanger sequencing of the TERT promoter region and CTNNB1 gene 
(PAPERS II-IV) 
Sanger sequencing is based on single-strand DNA template, DNA primers and DNA 
polymerase [120]. Both deoxy-ribonucleoside triphosphates (dNTPs) and 
dideoxynucleotide triphosphates (ddNTPs) lacking 3’-OH group were added into the 
PCR system [121]. Since ddNTPs cannot form phosphodiester bonds with the nucleotide 
next to it, the DNA amplification will be stopped when ddNTPs bind to the template. 
The ddNTPs were labeled by four different fluorescence dyes, so the different sized PCR 
fragments with different termination signal could be separated and detected by capillary 
electrophoresis and sequence analysis [122]. 
In PAPER II-IV, point mutations of the TERT promoter and CTNNB1 gene were 
detected using Sanger sequencing. Since the TERT promoter is a GC-rich region, 
bataine was added into the PCR system to increase PCR amplification efficiency 
[123-124]. After PCR reaction, products were purified with ExtraStar and then 
precipitated with EDTA and ethanol. Sanger sequencing was performed with Big Dye 
Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems) in ABI 3730 DNA analyzer 
machine. Primers used for Sanger sequencing are listed in Table 2. 
The results were analyzed with Codon Code Aligner software and the mutations were 
confirmed in both forward and reverse directions. 
Table 2. Primers used for PCR and Sanger sequencing 
TERT promoter 
Forward 5’-CACCCGTCCTGCCCCTTCACCTT-3’ 
Reverse 5’-GGCTTCCCACGTGCGCAGCAGGA-3’ 
CTNNB1 
Forward 5’-GGGTATTTGAAGTATACCATA-3’ 
Reverse 5’-TGGTCCTCGTCATTTAGCAG-3’ 
3.7 Competitive allele-specific TaqMan™ PCR (castPCR) (PAPER IV) 
castPCR analysis is highly specific and sensitive technology to detect rare amount of 
mutated DNA in a sample containing large amount of wild-type DNA [125-127]. In this 
study, it was performed by using ABI 7900 Real-time PCR system. The method requires 
genomic DNA template, mutant/wild type assay and 2×Taqman genotyping master 
mixture. The reaction system included 5 μl Taqman genotyping master mixture, 1 μl 
mutant/wild type assay, 2 μl DDW and 20 ng DNA template (diluted into 2 μl). The 
PCR conditions were: 95℃ for 10 mins, then (92℃ for 15s and 58℃ for 1 min) ×5 
cycles followed by 45 cycles of 92℃ for 15s and 60℃ for 1 min. The PCR result was 
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analyzed using SDS 2.4 software program and Mutation Detector Software 2.0 (Life 
technologies). 
For the sensitivity and specificity evaluation, the results from castPCR were compared 
with the results from Sanger sequencing, and the obtained results were also compared 
with the TERT promoter mutation status in tumors. 
3.8 Statistical analyses (PAPERS I-IV) 
The comparison of telomere length and mRNA expression was made using 2-tailed 
Student’s t-test or Mann-Whitney U test. For genotype distributions of TERT rs2736098 
and rs2736100, Fisher’s exact test was used to generate odd ratio (OR), 95% confidence 
interval (CI) and P-value (PAPER I). Sex and age were compared between patients and 
healthy controls using Chi-square test or Fisher’s exact test (PAPERS II-IV). Two-tailed 
student’s t-test was used to analyze differences in tumor sizes between the TERT 
promoter mutation-positive and negative patient groups. Sensitivity and specificity 
difference between castPCR and Sanger sequencing were evaluated using McNemar’s 
test (PAPER IV). All the tests were made using SigmaStat 3.1 software (Systat Software, 
Inc., Richmond, CA), and P-values<0.05 were considered as statistically significant. 
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4 RESULTS AND DISCUSSION 
4.1 TERT gene variation in cancer and clinical implication (PAPERS I-III) 
4.1.1 Distribution of TERT rs2736100 alleles in healthy Swedish and 
Chinese populations (PAPER I) 
The characteristics of the MPN patients and healthy controls are showed in table 3. 
Genotyping of rs2736100 was performed in Swedish and Chinese patients and healthy 
controls. The A-allele is more frequent in the Chinese cohort. Moreover we collected the 
published genotyping data from other cohorts from Shandong and Guangzhou areas, and 
both studies showed the rs2736100 genotype distribution to be similar to our data (Table 
4). The rs2736100 genotype distribution in healthy populations from Sweden and other 
European countries was also compared to that in China, and all of the published studies 
displayed similar rs2736100 variant frequency: lower A allele and higher C allele (48.0% 
vs 57.4% and 52.0% vs 42.6% for A and C, respectively, P＜ 0.001) (Table 4).   
Table 3. Characteristics of healthy controls and patients with MPN 
  Sweden China 
Controls MPN Controls MPN 
Number 756 126 101 101 
Age (years)     
Mean ± SD 64±5 64±14 58±15 58±15 
Median (range) 64(54-74) 65(25-106) 60(17-82) 60(17-82) 
Sex (% female) 53 53 50 50 
MPN subtype, n (%)     
    PV  41(32.5)  16(15.8) 
    ET  40(31.7)  38(37.6) 
    PMF  28(22.3)  15(14.9) 
    MPN-NOS  17(13.5)  32(31.7) 
JAK2-station, n (%)     
    JAK2 V617F
+
  60(47.6)  38(37.6) 
    JAK2 V617F
-
  66(52.4)  56(55.4) 
    Unknown  0  7(7.0) 
CALR mutation   45   Unknown 
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Table 4. Published rs2736100 genotype distributions of healthy populations in China and Europe 
Author Number AA (%) AC (%) CC (%) A (%) C (%) Area Reference 
China 
        
Dahlström et al 101 33(32.7) 50(49.5) 18(17.8) 116(57.4) 86(42.6) North
a
 This study 
    Yuan et al 289 86(29.8) 144(49.8) 59(20.4) 316(54.7) 262(45.3) North
a
 [128]  
    Wei et al 2520 814(32.3) 1269(50.4) 437(17.3) 2897(57.5) 2143(42.5) South
b
 [67] 
    Total 2910 933(32.1)* 1463(50.3)* 514(17.6)* 3329(57.2)* 2491(42.8)* 
  
Europe 
        
Dahlström et al 756 167(22.1) 377(49.9) 212(28.0) 711(47.0) 801(53.0) Sweden This study 
Jäger et al 202 47(23.3) 88(43.6) 67(33.2) 182(45.0) 222(55.0) Italy [129] 
Krahling et al 400 111(27.8) 188(47.0) 101(25.2) 410(51.3) 390(48.7) Hungary [130] 
    Total 1358 325(23.9)** 653(48.0)** 380(28.1)** 1303(48.0)** 1413(52.0)** 
 
  
AA vs 
AC+CC 
AC vs 
AA+CC 
CC vs 
AA+AC  
C va A 
  
p value (* vs **) 
 
＜0.001 0.106 ＜0.001 
 
＜0.001 
  
OR and p values were generated using chi-squared test 
a
From Shandong area; 
b
From Shanghai and Guangzhou areas 
 
 
1
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4.1.2 TERT SNP rs2736100_C is a risk factor for MPNs in males (PAPER 
I) 
Since rs2736100 allele has different distributions in control groups between China and 
Sweden, we decided to analyze MPN patients from these two countries separately. 
According to our analyses, both Chinese and Swedish MPN patients had a higher 
frequency of the rs2736100_C allele compared to their corresponding healthy controls 
(both P=0.004, Table 5). Compared to the AA variant carriers, both Swedish and 
Chinese patients bearing the CC genotype showed significantly increased risk of MPNs 
(OR = 2.47; 95% CI: 1.33 - 4.57, P = 0.003, for Swedish, and OR = 3.45; 95% CI: 1.52 - 
7.85, P = 0.005, for Chinese patients) (Table 5). Further analyses showed that the CC 
genotype and C allele had a higher frequency only in male MPN patients. 
Interestingly, we notice that the MPN incidence is much higher in Sweden (5.8/100,000) 
than in China (2/100,000) [131], which is correlated with their rs2736100_C allele 
frequencies. Racial or ethnic disparities in cancer incidence and pathogenesis due to 
different genetic backgrounds have been well characterized, and a difference in TERT 
rs2736100 variants between Swedish and Chinese populations may partially explain 
their differential MPN incidences.  
Table 5. Comparison of TERT rs2736100 genotypes in MPN patients and healthy controls 
rs2736100 
genotype 
Sweden China 
Controls 
n (%) 
MPN 
n (%) 
OR (95%CI) * 
p 
value 
Controls 
n (%) 
MPN 
n (%) 
OR (95%CI) * 
p 
value 
All 756 (100) 123 (100) 
  
101 (100) 101 (100) 
  
Alleles 
        
A 711 (47.0) 94 (37.3) 1.0 (ref) 
 
116 (57.4) 86 (42.6) 1.0 (ref) 
 
C 801 (53.0) 158 (62.7) 1.49 (1.13-1.96) 0.004 86 (42.6) 116 (57.4) 1.82 (1.23-2.70) 0.004 
Genotypes 
        
AA 167 (22.1) 15 (11.9) 1.0 (ref) 
 
33 (32.7) 17 (16.8) 1.0 (ref) 
 
AC 377 (49.9) 64 (50.8) 1.89 (1.05-3.41) 0.034 50 (49.5) 52 (51.5) 2.02 (1.00-4.08) 0.057 
CC 212 (28.0) 47 (37.3) 2.47 (1.33-4.57) 0.003 18 (17.8) 32 (31.7) 3.45 (1.52-7.85) 0.005 
AA+AC 544 (72.0) 79 (62.7) 1.0 (ref) 
 
83 (82.2) 69 (68.3) 1.0 (ref) 
 
CC 212 (28.0) 47 (37.3) 1.53 (1.03-2.27) 0.044 18 (17.8) 32 (31.7) 2.14 (1.11-4.14) 0.033 
AC+CC 589 (77.9) 111 (88.1) 1.0 (ref) 
 
68 (67.3) 84 (83.2) 1.0 (ref) 
 
AA 167 (22.1) 15 (11.9) 0.48 (0.27-0.84） 0.009 33 (32.7) 17 (16.8) 0.42 (0.21-0.81) 0.014 
*OR, Odds ratio; CI, Confidence interval 
OR and p values generated using Fishers' exact test Significant p values are shown in bold. 
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4.1.3 TERT mRNA expression and telomere length in patients with MPN 
carrying different TERT rs2736100 genotypes (PAPER I) 
MPN patients with the TERT rs2736100_CC genotype display the highest TERT mRNA 
expression in their myeloid cells compared with the AA and AC carrying patients (P = 
0.024) (Figure 3). The difference in TERT expression between the AC and AA variants 
was not significant. The rs2736100_CC-carrying patients tended to have longer telomere 
than did those with AA and AC genotypes; however, the difference did not reach 
statistical significance. 
The present finding is consistent with the result by Wei et al. [67], who observed that the 
rs2736100_CC genotype promoted TERT gene transcription and up-regulated 
telomerase activity more strongly than did AA or AC variants. Conceivably, higher 
TERT expression and telomerase activity facilitates the pathogenesis of MPNs via both 
telomere lengthening-dependent and independent mechanisms. 
 
 
 
4.1.4 TERT gene variation and UTUC risk (PAPER II) 
In this study, 212 UTUC patients were included, and the clinical characteristics are 
summarized in Table 6.  
 
 
 
 
Figure 3. TERT mRNA expression and telomere length in Swedish MPN patients with 
different TERT rs2736100 genotypes. * p<0.05. 
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Table 6. Clinical characteristics of patients with UTUC 
  RPC* UC* Total 
informative cases (n=) 92 120 212 
Age at diagnosis (n=212) 
   
    Mean ± SD 63±11 66±11 64±11 
    Median (range) years 64(36-85) 67(32-87) 66(32-87) 
Gender (n=212) 
   
    Female 37 45 82 
    Male 55 75 130 
Metastases or capsular invasion 
(n=189)    
    Yes 6 11 17 
    No 77 95 172 
Stage (n=189) 
   
    Pa+Ⅰ 16 24 40 
    PⅡ+Ⅲ+Ⅳ 67 82 149 
grades (n=189) 
   
    G1 13 12 25 
    G2 9 13 22 
    G3 61 81 142 
*RPC: Renal pelvic carcinoma; UC: Ureter carcinoma 
 
TERT rs2736100 AC and rs2736098 GT genotype were analyzed in the age- and 
sex-matched healthy population and UTUC patients. The genotype distributions are 
listed in Table 7. In UTUC patients, the prevalence of the rs2736100 heterozygous AC 
genotype was significantly lower than that in healthy controls, which indicates a 
reduced risk for UTUCs (Odds ratio = 0.583; 95% CI: 0.388 - 0.875; P = 0.012). When 
we combined the AA and CC genotypes together and compared with the AC variant, a 
significant difference remained (OR = 0.613, 95% CI: 0.428 - 0.879, P = 0.010) (Table 
7). 
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Table 7. TERT rs2736100 genotypes in healthy controls and patients with UTUC 
Genotype 
Control RPC* UC* Total UTUC 
N (%) N (%) Odds ratio (95% CI*) P N (%) Odds ratio (95% CI*) P N (%) Odds ratio (95% CI*) P 
rs2736100 (N/%) 289 92 
  
120 
  
212 
  AA 86 (29.8) 34 (37.0) 1.0 (ref.) 
 
49 (40.8) 1.0 (ref.) 
 
83 (39.2) 1.0 (ref.) 
 AC 144 (49.8) 32 (34.8) 0.562 (0.324 - 0.976) 0.055 49 (40.8) 0.597 (0.370 - 0.963) 0.045 81 (38.2) 0.583 (0.388 - 0.875) 0.012 
CC 59 (20.4) 26 (28.2) 1.115 (0.606 - 2.049) 0.846 22 (18.4) 0.714 (0.396 - 1.288) 0.330 48 (22.6) 0.878 (0.542 - 1.423) 0.685 
           AA + CC 145 (50) 60 (65) 1.0 (ref.) 
 
71 (59.2) 1.0 (ref.) 
 
133(62.1) 1.0 (ref.) 
 AC 144 (49.8) 32 (35) 1.862 (1.144 - 3.031) 0.016 49 (40.8) 0.695 (0.452 - 1.069) 0.121 81 (37.9) 0.613 (0.428 - 0.879) 0.010 
*RPC: Renal pelvic carcinoma; UC: Ureter carcinoma; CI: Confidence interval. Significant p values are shown in bold. 
 
 
 
 
 
 
1
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To see if the rs2736100_C allele showed any association with clinical variables, we 
analyzed the rs2736100 variants according to the disease stage and grade. A 
significantly negative association was found between the heterozygous rs2736100 AC 
genotype and early stage (pTa+T1) and low grades of UTUCs (OR = 0.358, 95% CI: 
0.167 - 0.769, P = 0.012) (Table 8). 
The present study is the first report showing the association between TERT SNPs and 
UTUC susceptibility. Moreover, we observed that the rs2736100 AC variant, a 
protective genotype, was significantly associated with a reduced risk for wt TERT 
promoter-carrying UTUCs. In addition, there exists an association between the 
rs2736100 AC genotype and reduced Ta and T1 stages of UTUCs. Thus, the germline 
TERT variants affect both UTUC susceptibility and disease progression. 
Table 8. Association of TERT rs2736100 variants with disease characteristics variables and TERT promoter 
mutations in patients with UTUC 
Genotype Cases Healthy controls Odds ratio (95% CI*) P-value 
Stages pTa - I vs controls 
    AA 20 (48.8%) 86 (29.8%) 1.0 (ref.) 
 AC 12 (29.2%) 144 (49.8%) 0.358 (0.167 - 0.769) 0.012 
CC 9 (22.0%) 59 (20.4%) 0.656 (0.279 - 1.540) 0.455 
Stages pII + III + IV vs controls 
    AA 50 (33.8%) 86 (29.8%) 1.0 (ref.) 
 AC 64 (43.2%) 144 (49.8%) 0.764 (0.484 - 1.206) 0.229 
CC 34 (23.0%) 59 (20.4%) 0.991 (0.573 - 1.713) 0.914 
Grade G1 vs controls  
    AA 10 (41.7%) 86 (29.8%) 1.0 (ref.) 
 AC 8 (33.3%) 144 (49.8%) 0.478 (0.182 - 1.257) 0.203 
CC 6 (25.0%) 59 (20.4%) 0.875 (0.301 - 2.537 0.983 
Grade G2 + G3 vs controls  
    AA 60 (36.4%) 86 (29.8%) 1.0 (ref.) 
 AC 68 (41.2%) 144 (49.8%) 0.675 (0.437 - 1.049) 0.101 
CC 37 (22.4%) 59 (20.4%) 0.899 (0.531 - 1.522) 0.793 
wt TERT promoter vs controls 
    AA 50 (37.5%) 86 (29.8%) 1.0 (ref.) 
 AC 50 (37.5%) 144 (49.8%) 0.597 (0.372 - 0.960) 0.044 
CC 33 (25.0%) 59 (20.4%) 0.962 (0.555 - 1.668) 0.988 
mt TERT promoter vs controls 
    AA 20 (35.7%) 86 (29.8%) 1.0 (ref.) 
 AC 26 (46.4%) 144 (49.8%) 0.776 (0.409 - 1.474) 0.543 
CC 10 (17.9%) 59 (20.4%) 0.729 (0.318 - 1.668) 0.586 
*CI: Confidence interval. Significant p values are shown in bold. 
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4.1.5 TERT rs2736098 and rs2736100 polymorphisms in HCC (PAPER III) 
The genotyping data were obtained from 240 healthy controls and 231 HCC patients 
for rs2736098 and 237 healthy controls and 201 HCC patients for rs2736100, 
respectively. The clinical characteristics are shown in Table 9. 
Table 9. TERT promoter mutations and clinical characteristics of HCC patients  
Variable 
TERT promoter 
mutated 
TERT promoter 
wild-type P value 
informative cases (n = 190 ) (n = 57 ) (n =133 ) 
Age at diagnosis (n = ) 56 128 0.191 
    Mean years 54.71 52.63 
     Median (range) years 55.5 (32 - 75) 51 (25 - 76) 
 Gender (n = ) 56 128 0.898 
    Female  8 19 
     Male  48 109 
 HBV infection* (n = ) 55 129 0.105 
    Yes 50 103 
     No 5 26 
 Cirrhosis (n = ) 57 130 0.394 
    Yes 30 58 
     No 27 72 
 α-fetoprotein (ng/ml) (n= ) 54 120 0.927 
<200 38 82 
     ≥ 200 16 38 
 Tumor size (n = ) 56 121 0.328 
< 5 cm 32 58 
 > 5 cm 24 63 
 Differentiation (n = ) 55 123 0.609 
    Well or moderate 37 89 
      Poor 18 34 
 CTNNB1 (n = ) or TERT (n = ) 19 49 0.535 
    mutated 6 11 
     wt 13 38 
 Metastases (n = ) 56 129 0.670 
    Yes 1 5 
     No 55 124 
 *HBV: Hepatitis B virus 
Table 10 shows the summary of genotyping results. For the rs2736098 genotype, there 
was no significant difference between HCC patients and healthy controls. The 
rs2736100_CC genotype was significantly lower in HCC patients compared to the 
healthy controls (OR = 0.544, 95% CI: 0.320 - 0.925, P = 0.034) (Table 10). However, 
the difference was no longer significant after Bonferroni correction. Taken together, 
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neither rs2736100 nor rs2736098 variants are associated with HCC susceptibility. 
Because there were only 200 patients in the present HCC cohort, our result is unlikely 
conclusive and further studies recruiting more patients with HCCs are required to 
validate our findings.  
Table 10. TERT rs2736098 and 2736100 genotyping in healthy adults and HCC patients 
Genotype HA* HCC Odds ratio (95% CI*) P value 
 rs2736098 (N) 240 (100%) 231 (100%) 
  TT 31 (12.9) 19 (8.2) 1.0 (ref.) 
 CT 115 (47.9) 127 (55.0) 1.802 (0.965 - 3.364) 0.088 
CC 94 (39.2) 85 (36.8) 1.475 (0.7763 - 2.804) 0.303 
CT + CC 209 (87.1) 212 (91.8) 1.655 (0.906 - 3.023) 0.133 
CC 94 (39.2) 85 (36.8) 1.0 (ref.) 
 TT + CT 146 (60.8) 146 (63.2) 1.106 (0.762 - 1.605) 0.664 
rs2736100 (N) 237 (100%) 201 (100%) 
  AA 69 (29.1) 74 (36.8) 1.0 (ref.) 
 AC 108 (45.6) 92 (45.8) 0.794 (0.517 - 1.221) 0.347 
CC 60 (25.3) 35 (17.4) 0.544 (0.320 - 0.925) 0.033 
AC + CC 168 (74.7) 127 (63.2) 0.705 (0.472 - 1.053) 0.107 
CC 60 (25.3) 35 (17.4) 1.0 (ref.) 
 AA + AC 177 (73.7) 166 (82.6) 1.608 (1.007 - 2.566) 0.06 
*HA: Healthy adults; CI: Confidence interval. Significant p value is shown in bold. 
4.2 TERT promoter mutations in human cancer 
4.2.1 TERT promoter mutations in HCC (PAPER III) 
For the HCC cohort, TERT promoter mutations were also analyzed and we identified the 
presence of the mutations in 30% (57/190) HCC patients (Table 9). In addition, the 
CTNNB1 gene, encoding β-Catenin, is frequently mutated in HCC [59, 132], and 
therefore we sequenced this gene for mutation detection in HCC tumors, too. The 
CTNNB1 mutation was identified in 17/83 (24.3%) of HCC tumors and was not 
associated with the TERT promoter mutation. Clinical characteristics were compared 
between patients with and without TERT promoter mutations in their tumors, and no 
significant difference was found regarding age, sex, HBV infection, liver cirrhosis, 
α-fetoprotein levels, tumor size, differentiation status or presence of metastasis.  
Analyzing the relationship between the rs2736098/rs2736100 genotype and TERT 
promoter mutations, we observed that HCC patients bearing a mutant TERT promoter 
had remarkably lower frequencies of rs2736098_TT and rs2736100_CC genotypes 
compared with those of healthy controls (mutant cases vs controls: 3.6% vs 12.9% and 
5.8% vs 25.3% for rs2736098_TT and rs2736100_CC, respectively) (Table 11). 
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Compared to rs2736098_TT cases, HCC patients with rs2736098_CT genotype 
exhibited increased frequency of TERT promoter-mutation (OR = 0.181, 95% CI: 0.054 
- 0.601, P = 0.004) (Table 11). 
Table 11.  TERT promoter mutations and association with rs2736100 and rs2736098 in HCC patients  
Genotype Cases 
Healthy 
controls Odds ratio (95% CI*) P value 
rs2736098 
 
    
 wt TERT promoter vs controls 128 (100%) 240 (100%) 
  TT 13 (10.1) 31 (12.9 ) 1.0 (Ref.) 
 CT 61 (47.7) 115 (47.9 ) 1.265 (0.617 - 2.594) 0.643 
CC 54 (42.2) 94 (39.2 ) 1.370 (0.661 - 2.840) 0.504 
TT 13 (10.1) 31 (12.9) 1.0 (Ref.) 
 CT + CC 115 (89.9) 209 (87.1) 1.310 (0.660 - 2.607) 0.543 
mt TERT promoter vs controls 55 (100%) 240 (100%) 
  TT 2 (3.6) 31 (12.9 ) 1.0 (Ref.) 
 CT 40 (72.7) 115 (47.9 ) 5.391 (1.234 - 23.553) 0.025 
CC 13 (23.7) 94 (39.2) 2.144 (0.458 - 10.030) 0.505 
TT 2 (3.6) 31 (12.9) 1.0 (Ref.) 
 CT + CC 53 (96.4) 209 (87.1) 3.931 (0.912 - 16.948) 0.083 
rs2736100 
    wt TERT promoter vs controls 114 (100%) 237 (100%) 
  AA 38 (33.3) 69 (29.1) 1.0 (Ref.) 
 CA 52 (45.6) 108 (45.6) 1.141 (0.683 - 1.916) 0.705 
CC 24 (21.1) 60 (25.3) 0.726 (0.392 - 1.346) 0.389 
AA + AC 90 (78.9) 177 (74.7) 1.0 (Ref.) 
 CC  24 (21.1) 60 (25.3) 0.787 ( 0.460 - 1.346) 0.457 
mt TERT promoter vs controls 52 (100%) 237 (100%) 
  AA 15 (28.8) 69 (29.1) 1.0 (Ref.) 
 CA 34 (65.4) 108 (45.6) 1.448 (0.735 - 2.854) 0.389 
CC 3 (5.8) 60 (25.3) 0.230 (0.0635 - 0.833) 0.032 
AA + AC 49 (94.2) 177 (74.7) 1.0 (Ref.) 
 CC  3 (5.8) 60 (25.3) 0.181 (0.0543 - 0.601) 0.004 
*CI: Confidence interval 
Significant p values are shown in bold. 
It is currently unclear why the TERT promoter mutation differs substantially from 
cancer to cancer, or from patient to patient with the same type of cancer. Here we 
observed that the germline TERT gene variants rs2736100_CC and rs2736098_TT were 
negatively associated with the mutation frequency, which might provide one potential 
explanation. As documented in PAPER I, the rs2736100_CC stimulates TERT 
expression and up-regulates telomerase activity more strongly than does the AA or AC 
genotype. Likely, patients with the AA/AC variants may face strong pressure of 
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telomere shortening in tumor cells, and are thus prone to undergo TERT promoter 
mutations, because very short telomeres have been identified to be a trigger for TERT 
promoter mutations [78]. Consistently, the rs2736100_AC frequency was significantly 
lower in UTUC patients with a wt TERT promoter (PAPER II). 
4.2.2 TERT promoter mutations in UTUCs and BCs (PAPER IV) 
Tumor DNA from 220 patients with UTUC was analyzed for the TERT promoter status. 
A total of 29% (65 cases) were identified to harbor TERT promoter mutations in their 
tumors. The clinical characteristics in relation to TERT promoter mutations are shown in 
table 12 and table 13. In addition, 41/70 (59%) BC patients were positive for TERT 
promoter mutations. 
Table 12. Clinical and disease characteristics in relation to TERT promoter mutations in patients with RPC 
  TERT promoter mutated TERT promoter wild-type p value 
informative cases (n=) 42 56 
 
Age at diagnosis (n=98) 
   
Mean ±SD 61.90 ±10.031 63.96 ±11.207 0.349 (n.s.) 
    Median (range) 64 (36-82) 65.5 (40-85) 
 
Sex (n=98) 
  
0.646 (n.s.) 
    Female 14 30 
 
    Male 28 26 
 
TNM stage (n=98) 
  
0.216 (n.s.) 
    pTa+pT1 6 14 
 
    ≥pT2 36 42 
 
Pathology stage (n=98) 
  
0.239 (n.s.) 
    G2 13 11 
 
    G3 29 45 
 
Tumor size (n=93) 
  
0.825 (n.s.) 
<3cm 13 16 
 
    ≥3cm 27 37 
 
Distant metastases (n=98) 
  
0.013 
    Yes 5 0 
 
    No 37 56 
 
Lymph node infiltration (n=98) 
  
0.069 (n.s.) 
    Yes 0 5 
 
    No 42 51   
n.s.: not statistically significant 
Significant p value is indicated in bold. 
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Table 13. Clinical and disease characteristics in relation to TERT promoter mutations in patients with UC 
  TERT promoter mutated TERT promoter wild-type p value 
informative cases (n=) 23 99 
 
Age at diagnosis (n=122) 
   
Mean±SD 72.39±8.994 65.05±9.612 0.001 
    Median (range) 75 (55-87) 67 (32-87) 
 
Sex (n=122) 
  
0.632 (n.s.) 
    Female 7 38 
 
    Male 16 61 
 
TNM stage (n=122) 
  
0.589 (n.s.) 
    pTa+pT1 4 25 
 
    ≥pT2 19 74 
 
Pathology stage (n=122) 
  
1.000 (n.s.) 
    G2 6 24 
 
    G3 17 75 
 
Tumor size (n=101 
  
0.623 (n.s.) 
<3cm 10 46 
 
    ≥3cm 10 35 
 
Distant metastases (n=122) 
  
0.046 
    Yes 3 2 
 
    No 20 97 
 
Lymph node infiltration (n=122) 
 
0.686 (n.s.) 
    Yes 1 9 
 
    No 22 90   
n.s.: not statistically significant 
Significant p values are indicated in bold. 
We found that frequency of mutations increased with age in patients with UCs but not in 
RPCs (P = 0.001 and 0.349, respectively) (Table 12 and Table 13). The distribution of 
sex, tumor size, clinical stage and local lymph node infiltration did not differ 
significantly between RPC or UC patients with and without TERT promoter mutations. 
However, distant metastasis was closely associated with the presence of TERT promoter 
mutations (P = 0.013, Fisher exact test) (Table 12). 
4.2.3 Detection of TERT promoter mutations in urine from UTUC patients 
by Sanger sequencing (PAPER IV) 
Using Sanger sequencing, 4 of 8 mutations-carriers could be detected in urine from RPC 
patients. For UC patients, 2 of 20 patients harbored TERT promoter mutations in their 
tumors and the same mutations were detected in urine from these two patients, too 
(Table 14). The Sanger sequencing results revealed the presence of a wt TERT promoter 
in the urine samples from the remaining 18 UC patients with a wt TERT promoter. 
Moreover, we also collected urine samples from 4 RPC and 9 UC patients one week 
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after surgery and all three patients with mutation-positive urine samples prior to 
operation became negative following surgical resection of tumors (Table 14). 
Taken together, Sanger sequencing showed a detection sensitivity of 60% with 96% 
specificity for urinary examination in UTUC patients. The mutant TERT promoter 
disappeared fast after surgical removal of tumors. Clearly, the assay sensitivity using 
Sanger sequencing is presently insufficient for clinical application, and a more sensitive, 
reliable approach has to be established. 
4.3 TERT promoter mutations as urinary biomarkers for UTUC diagnosis 
and disease monitoring (PAPER IV) 
Since TERT promoter mutations are absent in normal cells, the detection of the mutant 
TERT promoter as a diagnostic marker seems promising. For this purpose, we first 
performed analyses on the mixture of proportional mutant and wild type DNA using 
Sanger sequencing. We found that the detection threshold limit of Sanger sequencing 
was about 10% of mutant alleles present in mixed DNA samples. To improve the 
sensitivity of the assay, we developed a competitive Allele-specific TaqMan PCR 
(castPCR). By using this method, the threshold limit for measurement decreased from 
10% to 2.5% of mutant alleles present in mixed DNA samples (Figure 4A, 4C and 4D), 
which indicates at least a four-fold higher detection sensitivity by castPCR in 
comparison to Sanger sequencing (Figure. 4A and 4D). Consistently, the detection of 
the mutant TERT promoter in urine from UTUC and BC patients using castPCR 
showed significantly improved sensitivity (89%) without compromising specificity 
(96%, comparable to that by Sanger sequencing), which should have great potential for 
clinical implications. 
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Table 14. TERT promoter mutations detected on both tumor and urine samples from RPC and UC patients 
case 
number 
Sex 
M/F 
Age at 
diagnosis 
(year) 
Tumor size 
(cm) 
TNM 
stage 
TERT promoter mutation 
Tissue Preoperative urine Postoperative urine 
Sanger Sanger castPCR Sanger castPCR 
RPC-1 F 68 3.5 T1N0M0 wt wt wt wt wt 
RPC-2 F 66 3 T1N0M0 wt wt wt NA NA 
RPC-3 F 61 10 T1N0M0 wt wt wt NA NA 
RPC-4 M 71 8 T3N0M0 C228T C228T C228T NA NA 
RPC-5 M 43 5.5 T3N0M0 C228T wt C228T NA NA 
RPC-6 M 65 1.8 T1N0M0 wt wt wt wt wt 
RPC-7 F 82 6 T2N0M0 C228T C228T C228T wt wt 
RPC-8 M 79 1 T1N0M0 wt wt C228T NA NA 
RPC-9 M 71 3.5 T3N0M0 C228T wt C228T NA NA 
RPC-10 M 63 5 T4N0M0 C228T C228T C228T wt wt 
RPC-11 M 64 2.5 T3N0M0 C228T C228T C228T NA NA 
RPC-12 M 64 3 T2N0M0 C228T wt wt NA NA 
RPC-13 F 67 3.2 T1N0M0 C228T wt C228T NA NA 
RPC-14 M 80 4.8 T3N0M0 wt wt wt NA NA 
RPC-15 F 73 4.5 T2N0M0 wt wt wt NA NA 
RPC-16 M 57 2 T3N0M0 wt C228T C228T NA NA 
UC-1 M 67 2.5 T2N0M0 wt wt wt NA NA 
UC-2 F 72 0.3 T1N0M0 wt wt wt NA NA 
UC-3 F 68 1.7 T3N0M0 wt wt wt NA NA 
UC-4 M 71 1.2 TaN0M0 wt wt wt NA NA 
UC-5 M 67 4 T3N0M0 wt wt wt NA NA 
UC-6 M 61 2 T1N0M0 wt wt C228T NA NA 
UC-7 F 68 4.5 T1N0M0 wt wt wt NA NA 
UC-8 M 78 4.5 TaN0M0 C228T C228T C228T NA NA 
UC-9 F 67 1.6 T3N0M0 wt wt wt NA NA 
UC-10 F 54 4 T3N2M1 wt wt wt wt wt 
UC-11 M 65 3.5 T3N0M0 wt wt wt NA NA 
UC-12 M 50 2.2 T2N0M0 wt wt wt wt wt 
UC-13 F 58 1.9 T3N0M0 wt wt wt wt wt 
UC-14 M 49 3 T1N0M0 wt wt wt wt wt 
UC-15 M 70 4 T2N0M1 wt wt wt wt wt 
UC-16 F 65 1.7 T2N0M0 wt wt wt wt wt 
UC-17 F 61 1.6 T1N0M0 wt wt wt wt wt 
UC-18 F 61 5 T2N0M0 wt wt wt wt wt 
UC-19 M 57 1.5 T1N0M1 C228T C228T C228T wt wt 
UC-20 M 69 3.7 T3N0M0 wt wt wt NA NA 
RPC: Renal pelvic carcinoma; UC: Ureter carcinoma; M: Male; F: Female; castPCR: Competitive Allele-specific TaqMan PCR; 
NA: Not Available; wt: wild-type; Sanger: Sanger sequencing 
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Figure 4. The increased sensitivity for the castPCR detection of C228T mutations in urine 
derived from patients with renal pelvic and ureter carcinomas (RPCs and UCs). (A) The 
detection sensitivity of TERT promoter mutations as determined by Sanger sequencing. DNA 
derived from thyroid cancer cells with (homozygous) C228T mutation and with a wt TERT 
promoter was mixed as indicated and the promoter region then sequenced using Sanger sequencing. 
The detectable load of mutant DNA by Sanger sequencing was minimally 10%. (B) Sequencing 
chromatographs of the TERT promoter locus in urineDNA from onerenal pelvic carcinoma (RPC) 
and one ureter carcinoma (UC) patient, as determined by Sanger sequencing. C228T mutation was 
shown. (C) Schematic illustration of the castPCR detection of C228T mutation. The C228T and wt 
(reference) allele assays are performed with the allele-specific primer (ASP), locus-specific primer, 
allele-specific blocker (ASB) and locus-specific Taqman probe (LST). In mutant assays, ASB 
prevents wt TERT promoter sequences from PCR amplification. (D) Representative amplification 
plots for the assay of different proportions of C228T mutant allele as determined by castPCR. 
Mixed DNA as above in (A) was analyzed for the presence of the C228T mutation using castPCR. 
Left panel: The amplification plots for the wt (reference) TERT promoter. 99%, 97.5%, 95% and 
75% wt DNA-containing mixtures were amplified using LSP primers and wild type plots were 
generated. Of note, pure (100%) and 99% mutant DNA only yielded background signals. Right 
panel: The amplification plots for the mutant TERT promoter. The same DNA mixtures as 
described above were amplified using ASP primers and mutant amplification plots were generated. 
The CT value was inversely correlated with % of the mutant alleles. Of note, pure (100%) and 99% 
wt DNA-containing mixtures only gave rise to background signals. (E) C228T mutation-positive 
(Left) and Negative (Right) urine as revealed by castPCR. Shown are representative castPCR results 
obtained from two RPC patient urine samples. 
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5 SUMMARY AND CONCLUSIONS 
1. The frequency of the TERT gene rs2736100_C allele is associated with an 
increased risk for MPNs in both Swedish and Chinese males. The rs2736100_C 
allele frequency is much higher in the Swedish than in the Chinese population, 
which are coupled with a higher and lower incidences of MPNs in Sweden and 
China, respectively. Such difference in TERT rs2736100_C allele between 
Swedish and Chinese populations may thus partially explain their differential 
MPN incidences (PAPER I). 
 
2. The TERT rs2736100 AC genotype is associated with reduced risk of UTUCs in 
a Chinese Hans population (PAPER II). 
 
3. The cancer risk genotype rs2736100_CC was significantly associated with a 
lower incidence of TERT promoter mutations, while the rs2736098_CT 
genotype was significantly associated with the TERT promoter mutation-positive 
tumors in patients with HCC. This indicates that the germline TERT genetic 
background may substantially affect the frequency of TERT promoter mutations 
(PAPER III). 
 
4. TERT promoter mutations were detectable in urine from BC and UTUC patients, 
and this proof-of-concept study demonstrates that the mutant TERT promoter 
may serve as a useful urinary marker for non-invasive diagnosis and relapse 
monitoring of patients with BC and UTUC. We further developed the castPCR 
assay showing high sensitivity and specificity, which should have great potential 
for future clinical application (PAPER IV). 
  
  31 
6 ACKNOWLEDGEMENTS 
I gratefully acknowledge all the people who have given help to me during these exciting 
and colorful years for my PhD study. In particular I would like to thank: 
My main supervisor, Dawei Xu, for your guidance and advice in my research and life. 
You always support me and treat me as your own daughter. Thank you for your trust and 
encouragement all the time. 
My co-supervisor, Magnus Björkholm, for your endless support, for the wonderful 
meetings, and for the practical suggestions for thyroiditis. 
My co-supervisor, Hans-Erik Claesson, for always being positive and making the 
hematology lab a warmer place. I also thank you for your patience when I was new in 
the lab and have no idea for my project. 
My co-supervisor, Jan Sjöberg, for being a wonderful person and sharing your 
knowledge and ideas in science and lymphoma. 
My mentor, Louise Sjöholm, for those nice chats in the corridor. You are always 
warm-hearted. Thank you for your kind helps for my research and life. 
My supervisor at Shandong University in China, Jihui Jia, for taking me into your lab 
and for your endless support and encouragement during my study in Sweden. 
All my co-authors and collaborators, Kun Wang, Nan Ge, Li Liu, Jikai Liu, Feng 
Kong, Chang Wang, Hongbo Ren, Keqiang Yan, Sanyuan Hu, Zhonghua Xu, 
Yidong Fan, Shengtian Zhao, Cheng Liu, Yan Meng, Ping Li, Liu Yang, Leonie 
Saft, Mehran Ghaderi, Yabin Wei, Catharina Lavebratt, Chengyun Zheng, 
Guanghui Cheng, Fang Wang, Qing Sun, Kailin Li, Chao Sun, Zhaomin Lin, 
Yun Luan, Yiteng Xu, Shunzhen Zheng, Shuyan Li, Li Shen, Joanna S. Kritikou, 
Åsa Brunnström, Benjamin Pelcman, Maria Matl, Xinyan Miao, Frida Schain, Eva 
Melin, Lisa S. Westerberg, for your input on my study. It’s my honor to work with 
you.  
All my colleagues and friends in Hematology Lab, Meta Andersson, for being a so nice 
person who taught me a lot about the flow cytometer; Monica Ekberg, for sharing your 
knowledge and experience; Selina Parvin, for helping me with ordering and for the 
wonderful cakes you made for us; Klas Strååt, for helping me arrange all the things and 
the nice meetings we have; Mingmei Shang, for your selfless help and endless support, 
and Hongya Han, TianTian Liu, Xiaolu Zhang, Bingnan Li, Jenny Dahström, 
Xiuming Liang, Jingya Yu, Yujiao Wu, for the support and company. I would also 
 32 
like to thank all the people working in the corridor at L8:00 for a wonderful work 
environment and a big family, especially the breakfasts and seminars every Friday 
morning, 
All my friends in Sweden and in China, for opening a new world for me. Thank you for 
the memorable time we have. You enriched my life and made my PhD years much more 
meaningful. 
My doctors, Hans Johnsson and Jan Calissendorff, for saving me from fever and pain 
at a crucial time. 
My boyfriend, Lizhou Fan, for your understanding and support. You make my life more 
colorful. You are the sunshine.  
My dearest family, Mummy and Daddy, for your care. Your endless love will always 
support me. 
This study was supported by the Swedish Cancer Society, the Cancer Society in 
Stockholm, Stockholm Country Council and Karolinska Institutet Funds. I would also 
like to thank China Scholarship Council (CSC) for stipend support. 
  
  33 
7 REFERENCES 
[1] Muller H J. The remaking of chromosomes. Collecting Net, 1938, 13: 181-198. 
[2] McClintock B. The stability of broken ends of chromosomes in Zea mays. 
Genetics, 1941, 26(2): 234. 
[3] McClintock B. The fusion of broken ends of chromosomes following nuclear 
fusion. Proceedings of the National Academy of Sciences of the United States of 
America, 1942, 28(11): 458-463. 
[4] Blackburn E H. Switching and signaling at the telomere. Cell, 2001, 106(6): 
661-673. 
[5] Moyzis R K, Buckingham J M, Cram L S, et al. A highly conserved repetitive 
DNA sequence,(TTAGGG) n, present at the telomeres of human chromosomes. 
Proceedings of the National Academy of Sciences of the United States of America, 
1988, 85(18): 6622-6626. 
[6] Calado R T, Young N S. Telomere diseases. New England Journal of Medicine, 
2009, 361(24): 2353-2365. 
[7] De Lange T. Shelterin: the protein complex that shapes and safeguards human 
telomeres. Genes & Development, 2005, 19(18): 2100-2110. 
[8] Griffith J D, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large 
duplex loop. Cell, 1999, 97(4): 503-514. 
[9] Harley C B. Telomere loss: mitotic clock or genetic time bomb? Mutation 
Research/DNAging, 1991, 256(2-6): 271-282. 
[10] Shay J W, Roninson I B. Hallmarks of senescence in carcinogenesis and cancer 
therapy. Oncogene, 2004, 23(16): 2919. 
[11] Vaziri H, Dragowska W, Allsopp R C, et al. Evidence for a mitotic clock in human 
hematopoietic stem cells: loss of telomeric DNA with age. Proceedings of the 
National Academy of Sciences of the United States of America, 1994, 91(21): 
9857-9860. 
[12] Greider C W, Blackburn E H. The telomere terminal transferase of Tetrahymena is 
a ribonucleoprotein enzyme with two kinds of primer specificity. Cell, 1987, 51(6): 
887-898. 
[13] Greider C W, Blackburn E H. A telomeric sequence in the RNA of Tetrahymena 
telomerase required for telomere repeat synthesis. Nature, 1989, 337(6205): 
331-337. 
[14] Bodnar A G, Ouellette M, Frolkis M, et al. Extension of life-span by introduction 
of telomerase into normal human cells. Science, 1998, 279(5349): 349-352. 
[15] Cong Y S, Wright W E, Shay J W. Human telomerase and its regulation. 
Microbiology and Molecular Biology Reviews, 2002, 66(3): 407-425. 
 34 
[16] Hiyama E, Hiyama K. Telomere and telomerase in stem cells. British Journal of 
Cancer, 2007, 96(7): 1020-1024. 
[17] Shay J W, Bacchetti S. A survey of telomerase activity in human cancer. 
European Journal of Cancer, 1997, 33(5): 787-791. 
[18] Akagi T, Sasai K, Hanafusa H. Refractory nature of normal human diploid 
fibroblasts with respect to oncogene-mediated transformation. Proceedings of the 
National Academy of Sciences of the United States of America, 2003, 100(23): 
13567-13572. 
[19] Kim N W, Piatyszek M A, Prowse K R, et al. Specific association of human 
telomerase activity with immortal cells and cancer. Science, 1994: 2011-2015. 
[20] Hahn W C, Counter C M, Lundberg A S, et al. Creation of human tumour cells 
with defined genetic elements. Nature, 1999, 400(6743): 464-468. 
[21] Ding D, Zhou J, Wang M, et al. Implications of telomere‐independent activities 
of telomerase reverse transcriptase in human cancer. The FEBS Journal, 2013, 
280(14): 3205-3211. 
[22] Lindvall C, Hou M, Komurasaki T, et al. Molecular Characterization of Human 
Telomerase Reverse Transcriptase-immortalized Human Fibroblasts by Gene 
Expression Profiling. Cancer Research, 2003, 63(8): 1743-1747. 
[23] Ding D, Xi P, Zhou J, et al. Human telomerase reverse transcriptase regulates 
MMP expression independently of telomerase activity via NF-κB-dependent 
transcription. The FASEB Journal, 2013, 27(11): 4375-4383. 
[24] Liu Z, Li Q, Li K, et al. Telomerase reverse transcriptase promotes 
epithelial-mesenchymal transition and stem cell-like traits in cancer cells. 
Oncogene, 2013, 32(36): 4203-4213. 
[25] Zhang K, Guo Y, Wang X, et al. WNT/β-catenin directs self-renewal symmetric 
cell division of hTERThigh prostate cancer stem cells. Cancer Research, 2017, 
77(9): 2534-2547. 
[26] Park J I, Venteicher A S, Hong J Y, et al. Telomerase modulates Wnt signalling by 
association with target gene chromatin. Nature, 2009, 460(7251): 66-72. 
[27] Kilian A, Bowtell D D L, Abud H E, et al. Isolation of a candidate human 
telomerase catalytic subunit gene, which reveals complex splicing patterns in 
different cell types. Human Molecular Genetics, 1997, 6(12): 2011-2019. 
[28] Lingner J, Hughes T R, Shevchenko A, et al. Reverse transcriptase motifs in the 
catalytic subunit of telomerase. Science, 1997, 276(5312): 561-567. 
[29] Meyerson M, Counter C M, Eaton E N, et al. hEST2, the putative human 
telomerase catalytic subunit gene, is up-regulated in tumor cells and during 
immortalization. Cell, 1997, 90(4): 785-795. 
[30] Daniel M, Peek G W, Tollefsbol T O. Regulation of the human catalytic subunit of 
telomerase (hTERT). Gene, 2012, 498(2): 135-146. 
  35 
[31] Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic 
subunit (hTERT) gene promoter and identification of proximal core promoter 
sequences essential for transcriptional activation in immortalized and cancer cells. 
Cancer Research, 1999, 59(3): 551-557. 
[32] Cong Y S, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: 
organization of the gene and characterization of the promoter. Human Molecular 
Genetics, 1999, 8(1): 137-142. 
[33] Wu K J, Grandori C, Amacker M, et al. Direct activation of TERT transcription by 
c-MYC. Nature Genetics, 1999, 21(2): 220-224. 
[34] Xu D, Popov N, Hou M, et al. Switch from Myc/Max to Mad1/Max binding and 
decrease in histone acetylation at the telomerase reverse transcriptase promoter 
during differentiation of HL60 cells. Proceedings of the National Academy of 
Sciences of the United States of America, 2001, 98(7): 3826-3831. 
[35] Grandori C, Cowley S M, James L P, et al. The Myc/Max/Mad network and the 
transcriptional control of cell behavior. Annual Review of Cell and Developmental 
Biology, 2000, 16(1): 653-699. 
[36] Kyo S, Takakura M, Taira T, et al. Sp1 cooperates with c-Myc to activate 
transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic 
Acids Research, 2000, 28(3): 669-677. 
[37] Xiao X, Athanasiou M, Sidorov I A, et al. Role of Ets/Id proteins for telomerase 
regulation in human cancer cells. Experimental and Molecular Pathology, 2003, 
75(3): 238-247. 
[38] Xu D, Dwyer J, Li H, et al. Ets2 maintains hTERT gene expression and breast 
cancer cell proliferation by interacting with c-Myc. Journal of Biological 
Chemistry, 2008, 283(35): 23567-23580. 
[39] Endoh T, Tsuji N, Asanuma K, et al. Survivin enhances telomerase activity via 
up-regulation of specificity protein 1-and c-Myc-mediated human telomerase 
reverse transcriptase gene transcription. Experimental Cell Research, 2005, 305(2): 
300-311. 
[40] Nishi H, Nakada T, Kyo S, et al. Hypoxia-inducible factor 1 mediates upregulation 
of telomerase (hTERT). Molecular and Cellular Biology, 2004, 24(13): 
6076-6083. 
[41] Deng W G, Jayachandran G, Wu G, et al. Tumor-specific activation of human 
telomerase reverses transcriptase promoter activity by activating enhancer-binding 
protein-2β in human lung cancer cells. Journal of Biological Chemistry, 2007, 
282(36): 26460-26470. 
[42] Lin S Y, Elledge S J. Multiple tumor suppressor pathways negatively regulate 
telomerase. Cell, 2003, 113(7): 881-889. 
 36 
[43] Günes Ç, Lichtsteiner S, Vasserot A P, et al. Expression of the hTERT gene is 
regulated at the level of transcriptional initiation and repressed by Mad1. Cancer 
Research, 2000, 60(8): 2116-2121. 
[44] Ge Z, Li W, Wang N, et al. Chromatin remodeling: recruitment of histone 
demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, 
telomerase reverse transcriptase. The FASEB Journal, 2010, 24(2): 579-586. 
[45] Casillas M A, Brotherton S L, Andrews L G, et al. Induction of endogenous 
telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific 
genetic elements. Gene, 2003, 316: 57-65. 
[46] Xu D, Wang Q, Gruber A, et al. Downregulation of telomerase reverse 
transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene, 
2000, 19(45): 5123-5133. 
[47] Kanaya T, Kyo S, Hamada K, et al. Adenoviral expression of p53 represses 
telomerase activity through down-regulation of human telomerase reverse 
transcriptase transcription. Clinical Cancer Research, 2000, 6(4): 1239-1247. 
[48] Lin S Y, Elledge S J. Multiple tumor suppressor pathways negatively regulate 
telomerase. Cell, 2003, 113(7): 881-889. 
[49] Oh S, Song Y, Yim J, et al. The Wilms' tumor 1 tumor suppressor gene represses 
transcription of the human telomerase reverse transcriptase gene. Journal of 
Biological Chemistry, 1999, 274(52): 37473-37478. 
[50] Takakura M, Kyo S, Inoue M, et al. Function of AP-1 in transcription of the 
telomerase reverse transcriptase gene (TERT) in human and mouse cells. 
Molecular and Cellular Biology, 2005, 25(18): 8037-8043. 
[51] Xu H J, Zhou Y, Ji W, et al. Reexpression of the retinoblastoma protein in tumor 
cells induces senescence and telomerase inhibition. Oncogene, 1997, 15(21): 
2589-2596. 
[52] Li H, Xu D, Li J, et al. Transforming growth factor β suppresses human 
telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and 
the hTERT gene. Journal of Biological Chemistry, 2006, 281(35): 25588-25600. 
[53] Rafnar T, Sulem P, Stacey S N, et al. Sequence variants at the TERT-CLPTM1L 
locus associate with many cancer types. Nature Genetics, 2009, 41(2): 221-227. 
[54] Wang Z, Zhu B, Zhang M, et al. Imputation and subset-based association analysis 
across different cancer types identifies multiple independent risk loci in the 
TERT-CLPTM1L region on chromosome 5p15. 33. Human Molecular Genetics, 
2014, 15;23(24):6616-6633. 
[55] Shete S, Hosking F J, Robertson L B, et al. Genome-wide association study 
identifies five susceptibility loci for glioma. Nature Genetics, 2009, 41(8): 
899-904. 
  37 
[56] Horn S, Figl A, Rachakonda P S, et al. TERT promoter mutations in familial and 
sporadic melanoma. Science, 2013, 339(6122): 959-961. 
[57] Killela P J, Reitman Z J, Jiao Y, et al. TERT promoter mutations occur frequently 
in gliomas and a subset of tumors derived from cells with low rates of self-renewal. 
Proceedings of the National Academy of Sciences of the United States of America, 
2013, 110(15): 6021-6026. 
[58] Remke M, Ramaswamy V, Peacock J, et al. TERT promoter mutations are highly 
recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 
126(6): 917-929. 
[59] Nault J C, Mallet M, Pilati C, et al. High frequency of telomerase 
reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and 
preneoplastic lesions. Nature Communications, 2013, 4: 2218. 
[60] Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in 
human cancers. Nature Communications, 2013, 4: 2185. 
[61] Landa I, Ganly I, Chan T A, et al. Frequent somatic TERT promoter mutations in 
thyroid cancer: higher prevalence in advanced forms of the disease. The Journal of 
Clinical Endocrinology & Metabolism, 2013, 98(9): 1562-1566. 
[62] Tallet A, Nault J C, Renier A, et al. Overexpression and promoter mutation of the 
TERT gene in malignant pleural mesothelioma. Oncogene, 2014, 33(28): 
3748-3752. 
[63] Heidenreich B, Nagore E, Rachakonda P S, et al. Telomerase reverse transcriptase 
promoter mutations in primary cutaneous melanoma. Nature Communications, 
2014, 5: 3401. 
[64] Hosen I, Rachakonda P S, Heidenreich B, et al. TERT promoter mutations in clear 
cell renal cell carcinoma. International Journal of Cancer, 2015, 136(10): 
2448-2452. 
[65] Scott G A, Laughlin T S, Rothberg P G. Mutations of the TERT promoter are 
common in basal cell carcinoma and squamous cell carcinoma. Modern Pathology, 
2014, 27(4): 516-523. 
[66] Chen X F, Cai S, Chen Q G, et al. Multiple variants of TERT and CLPTM1L 
constitute risk factors for lung adenocarcinoma. Genetic and Molecular Research, 
2012, 11(1): 370-378. 
[67] Wei R, Cao L, Pu H, et al. TERT Polymorphism rs2736100-C Is Associated with 
EGFR Mutation–Positive Non–Small Cell Lung Cancer. Clinical Cancer 
Research, 2015, 21(22): 5173-5180. 
[68] Zou P, Gu A, Ji G, et al. The TERT rs2736100 polymorphism and cancer risk: a 
meta-analysis based on 25 case-control studies. BMC Cancer, 2012, 12(1): 7. 
 38 
[69] Li T, Xian Y, Tian T, et al. New evidence of TERT rs2736098 polymorphism and 
cancer risk: an updated meta-analysis. Journal of B. U. ON. : official Journal of 
the Balkan Union of Oncology, 2016, 21(2): 491-497. 
[70] Wu H, Qiao N, Wang Y, et al. Association between the telomerase reverse 
transcriptase (TERT) rs2736098 polymorphism and cancer risk: evidence from a 
case-control study of non-small-cell lung cancer and a meta-analysis. PloS One, 
2013, 8(11): e76372. 
[71] Choi J E, Kang H G, Jang J S, et al. Polymorphisms in telomere maintenance 
genes and risk of lung cancer. Cancer Epidemiology and Prevention Biomarkers, 
2009, 18 (10), DOI: 10.1158/1055-9965.EPI-09-0323. 
[72] Savage S A, Chanock S J, Lissowska J, et al. Genetic variation in five genes 
important in telomere biology and risk for breast cancer. British Journal of Cancer, 
2007, 97(6): 832-836. 
[73] Huang F W, Hodis E, Xu M J, et al. Highly recurrent TERT promoter mutations in 
human melanoma. Science, 2013, 339(6122): 957-959. 
[74] Wu S, Huang P, Li C, et al. Telomerase reverse transcriptase gene promoter 
mutations help discern the origin of urogenital tumors: a genomic and molecular 
study. European Urology, 2014, 65(2): 274-277. 
[75] Liu T, Liang X, Björkholm M, et al. The absence of TERT promoter mutations in 
primary gastric cancer. Gene, 2014, 540(2): 266-267. 
[76] Stoehr R, Taubert H, Zinnall U, et al. Frequency of TERT promoter mutations in 
prostate cancer. Pathobiology, 2015, 82(2): 53-57. 
[77] Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT 
promoter commonly occur in adult malignant gliomas and are strongly associated 
with total 1p19q loss. Acta Neuropathologica, 2013, 126(2): 267-276. 
[78] Liu T, Wang N, Cao J, et al. The age-and shorter telomere-dependent TERT 
promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene, 2014, 
33(42): 4978-4984. 
[79] Patel U, Luthra R, Medeiros L J, et al. Diagnostic, Prognostic, and Predictive 
Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. Clinical 
Lymphoma Myeloma and Leukemia, 2017, 17: S62-S74. 
[80] Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a 
user’s manual. ASH Education Program Book, 2016, 2016(1): 534-542. 
[81] Kralovics R, Passamonti F, Buser A S, et al. A gain-of-function mutation of JAK2 
in myeloproliferative disorders. New England Journal of Medicine, 2005, 352(17): 
1779-1790. 
[82] Levine R L, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase 
JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia 
with myelofibrosis. Cancer Cell, 2005, 7(4): 387-397. 
  39 
[83] Barbui T, Falanga A. Molecular biomarkers of thrombosis in myeloproliferative 
neoplasms. Thrombosis Research, 2016, 140: S71-S75. 
[84] Spanoudakis E, Bazdiara I, Pantelidou D, et al. Dynamics of telomere's length and 
telomerase activity in Philadelphia chromosome negative myeloproliferative 
neoplasms. Leukemia Research, 2011, 35(4): 459-464. 
[85] Bernard L, Belisle C, Mollica L, et al. Telomere length is severely and similarly 
reduced in JAK2V617F-positive and-negative myeloproliferative neoplasms. 
Leukemia, 2009, 23(2): 287-291. 
[86] Elena C, Rumi E, Portolan M, et al. Flow-FISH evaluation of telomere length in 
Philadelphia-negative myeloproliferative neoplasms.  Haematologica, 2011, 
96(8): 1236-1238. 
[87] Ci X, Li B, Ma X, et al. Bortezomib-mediated down-regulation of telomerase and 
disruption of telomere homeostasis contributes to apoptosis of malignant cells. 
Oncotarget, 2015, 6(35): 38079-38092. 
[88] Dahlström J, Zhang X, Ghaderi M, et al. Dysregulation of shelterin factors coupled 
with telomere shortening in Philadelphia chromosome negative myeloproliferative 
neoplasms. Haematologica, 2015, 100(10): e402-e405. 
[89] Oddsson A, Kristinsson S Y, Helgason H, et al. The germline sequence variant 
rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia, 
2014, 28(6): 1371-1374. 
[90] Trifa A P, Bănescu C, Tevet M, et al. TERT rs2736100 A> C SNP and JAK2 46/1 
haplotype significantly contribute to the occurrence of JAK2 V617F and CALR 
mutated myeloproliferative neoplasms–a multicentric study on 529 patients. 
British Journal of Haematology, 2016, 174(2): 218-226. 
[91] Tefferi A, Lasho T L, Begna K H, et al. A pilot study of the telomerase inhibitor 
imetelstat for myelofibrosis. New England Journal of Medicine, 2015, 373(10): 
908-919. 
[92] Mosoyan G, Kraus T, Ye F, et al. Imetelstat, a telomerase inhibitor, differentially 
affects normal and malignant megakaryopoiesis. Leukemia, advance online 
publication, 24 March 2017, DOI: 10.1038/leu.2017.78. 
[93] Park J C, Hahn N M. Bladder cancer: a disease ripe for major advances. Clin. Adv. 
Hematol. Oncol., 2014, 12: 838-845 
[94] Mbeutcha A, Mathieu R, Rouprêt M, et al. Predictive models and prognostic 
factors for upper tract urothelial carcinoma: a comprehensive review of the 
literature. Translational Andrology and Urology, 2016, 5(5): 720-734. 
[95] Nison L, Rouprêt M, Bozzini G, et al. The oncologic impact of a delay between 
diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper 
urinary tract urothelial carcinomas: results from a large collaborative database. 
World Journal of Urology, 2013, 31(1): 69-76. 
 40 
[96] Park J C, Hahn N M. Bladder cancer: a disease ripe for major advances. Clin. Adv. 
Hematol. Oncol., 2014, 12(12): 838-845. 
[97] Siegel, R. L., Miller, K. D. and Jemal, A., Cancer statistics, 2017. CA: A Cancer 
Journal for Clinicians, 67: 7–30. DOI:10.3322/caac.21387 
[98] Hutchinson R, Haddad A, Sagalowsky A, et al. Upper tract urothelial carcinoma: 
special considerations. Clin. Adv. Hematol. Oncol., 2016, 14: 101-109. 
[99] Yamashita T, Wang X W. Cancer stem cells in the development of liver cancer. 
The Journal of Clinical Investigation, 2013, 123(5): 1911-1918. 
[100] Mittal S, El-Serag H B. Epidemiology of HCC: consider the population. Journal of 
Clinical Gastroenterology, 2013, 47: S2-S6. 
[101] Xu W, Yu J, Wong V W S. Mechanism and prediction of HCC development in 
HBV infection. Best Practice & Research Clinical Gastroenterology, 2017, 31(3): 
291-298. 
[102] Chen C H, Huang G T, Yang P M, et al. Hepatitis B-and C-related hepatocellular 
carcinomas yield different clinical features and prognosis. European Journal of 
Cancer, 2006, 42(15): 2524-2529. 
[103] Simonetti J, Bulkow L, McMahon B J, et al. Clearance of hepatitis B surface 
antigen and risk of hepatocellular carcinoma in a cohort chronically infected with 
hepatitis B virus. Hepatology, 2010, 51(5): 1531-1537. 
[104] Chen C H, Huang G T, Yang P M, et al. Hepatitis B-and C-related hepatocellular 
carcinomas yield different clinical features and prognosis. European Journal of 
Cancer, 2006, 42(15): 2524-2529. 
[105] Mohamad B, Shah V, Onyshchenko M, et al. Characterization of hepatocellular 
carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without 
cirrhosis. Hepatology International, 2016, 10(4): 632-639. 
[106] Perz J F, Armstrong G L, Farrington L A, et al. The contributions of hepatitis B 
virus and hepatitis C virus infections to cirrhosis and primary liver cancer 
worldwide. Journal of Hepatology, 2006, 45(4): 529-538. 
[107] Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption 
and their interaction in the causation of hepatocellular carcinoma. International 
Journal of Cancer, 2000, 85(4): 498-502. 
[108] Kim H, Yoo J E, Cho J Y, et al. Telomere length, TERT and shelterin complex 
proteins in hepatocellular carcinomas expressing “stemness”-related markers. 
Journal of Hepatology, 2013, 59(4): 746-752. 
[109] Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic 
mutations and focal copy-number changes identifies key genes and pathways in 
hepatocellular carcinoma. Nature Genetics, 2012, 44(6): 694-698. 
[110] Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling 
gene ARID2 in hepatocellular carcinoma. Nature Genetics, 2011, 43(9): 828-829. 
  41 
[111] Heaphy C M, Subhawong A P, Hong S M, et al. Prevalence of the alternative 
lengthening of telomeres telomere maintenance mechanism in human cancer 
subtypes. The American Journal of Pathology, 2011, 179(4): 1608-1615. 
[112] Nault J C, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. 
Clinics and Research in Hepatology and Gastroenterology, 2016, 40(1): 9-14. 
[113] Zhang C, Tian Y P, Wang Y, et al. hTERT rs2736098 genetic variants and 
susceptibility of hepatocellular carcinoma in the Chinese population: a 
case-control study. Hepatobiliary & Pancreatic Diseases International, 2013, 
12(1): 74-79. 
[114] Ding C Y, Hu L M, Hu Z B, et al. The relationship between gene polymorphism of 
telomerase reverse transcriptase and susceptibility to hepatocellular carcinoma. 
Zhonghua yu fang yi xue za zhi [Chinese Journal of Preventive Medicine], 2011, 
45(7): 593-596. 
[115] Ko E, Seo H W, Jung E S, et al. The TERT promoter SNP rs2853669 decreases 
E2F1 transcription factor binding and increases mortality and recurrence risks in 
liver cancer. Oncotarget, 2016, 7(1): 684-699. 
[116] Baerlocher G M, Vulto I, De Jong G, et al. Flow cytometry and FISH to measure 
the average length of telomeres (flow FISH). Nature Protocols, 2006, 1(5): 
2365-2376. 
[117] Livak K J, Schmittgen T D. Analysis of relative gene expression data using 
real-time quantitative PCR and the 2− ΔΔCT method. Methods, 2001, 25(4): 
402-408. 
[118] Wei Y B, Martinsson L, Liu J J, et al. hTERT genetic variation in depression. 
Journal of Affective Disorders, 2016, 189: 62-69. 
[119] McGuigan F E A, Ralston S H. Single nucleotide polymorphism detection: allelic 
discrimination using TaqMan. Psychiatric Genetics, 2002, 12(3): 133-136. 
[120] Sanger F, Coulson A R. A rapid method for determining sequences in DNA by 
primed synthesis with DNA polymerase. Journal of Molecular Biology, 1975, 
94(3): 441-448. 
[121] Sanger F, Nicklen S, Coulson A R. DNA sequencing with chain-terminating 
inhibitors. Proceedings of the National Academy of Sciences of the United States 
of America , 1977, 74(12): 5463-5467. 
[122] Niedringhaus T P, Milanova D, Kerby M B, et al. Landscape of next-generation 
sequencing technologies. Analytical Chemistry, 2011, 83(12): 4327-4341. 
[123] Henke W, Herdel K, Jung K, et al. Betaine improves the PCR amplification of 
GC-rich DNA sequences. Nucleic Acids Research, 1997, 25(19): 3957-3958. 
[124] Pinyol R, Tovar V, Llovet J M. TERT promoter mutations: gatekeeper and driver 
of hepatocellular carcinoma. Journal of Hepatology, 2014, 61(3): 685-687. 
 42 
[125] Tan R, Brzoska P, Chen C. Direct detection of rare circulating tumor cells in blood 
by castPCR. Journal of Biomolecular Techniques: JBT, 2010, 21(3 Suppl): S30. 
[126] Cheng W, Lasater E, Smith C C, et al. Competitive Allele Specific TaqMan® PCR 
(castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 
Kinase Domain Mutations in Primary AML Patient Samples. Blood, 2012, 120: 
2559. 
[127] Roma C, Esposito C, Rachiglio A M, et al. Detection of EGFR mutations by 
TaqMan mutation detection assays powered by competitive allele-specific 
TaqMan PCR technology. BioMed Research International, 2013, Article ID: 
385087. 
[128] Yuan X, Liu C, Wang K, et al. The genetic difference between Western and 
Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese 
patients. Oncotarget, 2016, 7(18): 25826-25835. 
[129] Krahling T, Balassa K, Kiss K P, et al. Co-occurrence of myeloproliferative 
neoplasms and solid tumors is attributed to a synergism between cytoreductive 
therapy and the common TERT polymorphism rs2736100. Cancer Epidemiology 
and Prevention Biomarkers, 2016 Jan;25(1):98-104. 
[130] Jäger R, Harutyunyan A S, Rumi E, et al. Common germline variation at the 
TERT locus contributes to familial clustering of myeloproliferative neoplasms. 
American Journal of Hematology, 2014, 89(12): 1107-1110. 
[131] Hultcrantz M, Andersson T M L, Landgren O, et al. A population-based study of 
incidence of myeloproliferative neoplasms in Sweden between 2000 and 2012. 
Orlando: American Society of Hematology 57th Annual Meeting and Exposition; 
2015. 
[132] Pezzuto F, Buonaguro L, Buonaguro F M, et al. Frequency and geographic 
distribution of TERT promoter mutations in primary hepatocellular carcinoma. 
Infectious Agents and Cancer, 2017, 12: 27. 
